How Much Does Multaq Cost?

Our most recent US pharmacy data shows a low of roughly $750.68 for Multaq with a standard discount card. That figure moves with dosage and quantity — check the comparison table for the exact combination you need.

We found Canadian pricing for Multaq starting near $2.16 per tablet in USD terms. That's before any shipping charge, which the table above breaks out separately.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. Check the comparison table above for the specific numbers on Multaq.

Generic and brand-name pricing for Multaq is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.

Most commercial insurance plans provide some coverage for Multaq, but your specific out-of-pocket cost—whether a copay or coinsurance—depends entirely on your plan's formulary and benefit design. It's important to contact your insurance provider or speak with your pharmacist to understand your expected cost. In some cases, the price obtained through a pharmacy discount program may be lower than your insurance copay, so comparing all available options at the pharmacy counter is advisable.

Multaq is often included on Medicare Part D formulary lists, but coverage and patient cost-sharing vary widely between individual plans. Your out-of-pocket expense will depend on your plan's specific phase (deductible, initial coverage, etc.), the dosage prescribed, and the pharmacy you use. To get an accurate estimate, consult your Medicare plan administrator or a pharmacist. For some beneficiaries, using a prescription discount card could result in a lower price than their Medicare copay, making it worthwhile to explore all savings avenues.

No, a generic equivalent for Multaq (dronedarone) is not currently on the market in the United States. The brand manufacturer, Sanofi, received patent approval in 2009, and based on typical patent timelines, a generic version is not expected to receive FDA approval until around 2029.